Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib

Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib

Abstract Gefitinib is the molecular target drug for advanced non‐small‐cell lung cancer. The primary target of gefitinib is the positive mutation of epidermal growth factor receptor, but it also inhibits cyclin G‐associated kinase (GAK). To reveal the molecular bases of GAK and gefitinib binding, st...

Full description

Bibliographic Details
Main Authors: Dr. Naomi Ohbayashi, Dr. Kazutaka Murayama, Miyuki Kato‐Murayama, Dr. Mutsuko Kukimoto‐Niino, Dr. Tamami Uejima, Dr. Takayoshi Matsuda, Dr. Noboru Ohsawa, Prof. Shigeyuki Yokoyama, Prof. Hiroshi Nojima, Dr. Mikako Shirouzu
Format: Article
Language:English
Published: Wiley-VCH 2018-09-01
Series:ChemistryOpen
Subjects:
complex structures
gefitinib
inhibitor development
novel binding sites
protein kinases
Online Access:https://doi.org/10.1002/open.201800177

Internet

https://doi.org/10.1002/open.201800177

Similar Items